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identifies two functionally deleterious rare
variants in systemic lupus erythematosus cases
Amy L Roberts1, Ellen RA Thomas2, Shriram Bhosle2, Laurence Game2, Olga Obraztsova1, Timothy J Aitman2,
Timothy J Vyse1* and Benjamin Rhodes1Abstract
Introduction: The majority of the genetic variance of systemic lupus erythematosus (SLE) remains unexplained by the
common disease-common variant hypothesis. Rare variants, which are not detectable by genome-wide association
studies because of their low frequencies, are predicted to explain part of this ”missing heritability.” However, recent
studies identifying rare variants within known disease-susceptibility loci have failed to show genetic associations
because of their extremely low frequencies, leading to the questioning of the contribution of rare variants to disease
susceptibility. A common (minor allele frequency = 17.4% in cases) nonsynonymous coding variant rs1143679 (R77H) in
ITGAM (CD11b), which forms half of the heterodimeric integrin receptor, complement receptor 3 (CR3), is robustly
associated with SLE and has been shown to impair CR3-mediated phagocytosis.
Methods: We resequenced ITGAM in 73 SLE cases and identified two previously unidentified, case-specific
nonsynonymous variants, F941V and G1145S. Both variants were genotyped in 2,107 and 949 additional SLE cases,
respectively, to estimate their frequencies in a disease population. An in vitro model was used to assess the impact
of F941V and G1145S, together with two nonsynonymous ITGAM polymorphisms, A858V (rs1143683) and M441T
(rs11861251), on CR3-mediated phagocytosis. A paired two-tailed t test was used to compare the phagocytic
capabilities of each variant with that of wild-type CR3.
Results: Both rare variants, F941V and G1145S, significantly impair CR3-mediated phagocytosis in an in vitro model
(61% reduction, P = 0.006; 26% reduction, P = 0.0232). However, neither of the common variants, M441T and A858V,
had an effect on phagocytosis. Neither rare variant was observed again in the genotyping of additional SLE cases,
suggesting that their frequencies are extremely low.
Conclusions: Our results add further evidence to the functional importance of ITGAM in SLE pathogenesis through
impaired phagocytosis. Additionally, this study provides a new example of the identification of rare variants in
common-allele-associated loci, which, because of their extremely low frequencies, are not statistically associated.
However, the demonstration of their functional effects adds support to their contribution to disease risk, and questions
the current notion of dismissing the contribution of very rare variants on purely statistical analyses.* Correspondence: Timothy.vyse@kcl.ac.uk
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Full list of author information is available at the end of the article
© 2014 Roberts et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Roberts et al. Arthritis Research & Therapy 2014, 16:R114 Page 2 of 11
http://arthritis-research.com/content/16/3/R114Introduction
Systemic lupus erythematosus (SLE) is a phenotypically
heterogeneous autoimmune disease resulting from the
breakdown of immune tolerance. SLE has a strong and
complex genetic component, as shown by estimates of
twin concordance [1]. Although 52 genetic loci now are
independently associated with SLE, the vast majority of
which are products of the genome-wide technologic
advancements of recent years, only an estimated 16% of
the total variance is thought to be explained [2,3] (J.
Bentham, D. L. Morris, et al. 2014, unpublished data].
The genome-wide association study (GWAS) era has
uncovered a plethora of common alleles, mostly of modest
effect sizes (odds ratio (OR), <2), associated with complex
diseases under the common disease-common variant
(CDCV) hypothesis [4]. Yet for most of these diseases, as
with SLE, the amount of remaining unexplained genetic
variance (the so-called missing heritability) is higher than
initially anticipated [5-7]. Rare variants with larger effect
sizes (OR, ≥2), but present at frequencies below the de-
tectable threshold of GWAS (<5%), have been hypothe-
sized to explain part of this ”missing” genetic effect [8,9].
Although they are individually rare, they are collectively
common and therefore may make a significant contribu-
tion to disease risk on a population level.
Because of their low frequency and incomplete pene-
trance, individual rare variants may never reach statisti-
cally significant levels of association, irrespective of very
large sample sizes [10]. Furthermore, the relatively high de
novo mutation rate in humans [11], means that chromo-
somes of unaffected individuals will also harbor rare, or
even private, mutations that may or may not influence dis-
ease risk. Genome- or exome-wide sequencing may un-
cover many new variants, but determining which of these
are functionally relevant is not easy by genetic analysis
alone [12]. One approach is to use the notable common
variant discoveries of GWAS to focus on resequencing
candidate genes that are already known to contain com-
mon disease-risk variants. Many studies have now identi-
fied additional rare variants in GWAS-associated loci
[13,14]. The largest of such studies focused on the coding
exons of 25 autoimmune GWAS-associated loci and
concluded that a negligible affect from rare variants was
present [15]. Ultimately, however, functional analyses of
rare variants will best enable us to understand the import-
ance of associated loci in disease pathogenesis and add
confirmatory evidence to disease biology paradigms estab-
lished by the functional effect of common variants.
SLE is robustly associated with ITGAM (ENSG00000
169896), which encodes CD11b [16]. Through non-
covalent binding with CD18, this forms the hetero-
dimeric integrin complement receptor 3 (CR3; Mac-1;
CD11b/CD18), expressed on phagocytes and NK cells
[17]. Despite the high degree of linkage disequilibrium(LD) across the ITGAM locus in European populations,
transancestral mapping provided evidence that the com-
mon nonsynonymous polymorphism rs1143679, encoding
an arginine-to-histidine amino acid change at codon 77
of CD11b (R77H), was the true causal SNP [18]. Subse-
quently, functional evidence supported this genetic associ-
ation, showing that R77H impairs many functions of the
CR3 receptor, including the phagocytosis of iC3b-coated
targets by ex vivo monocyte-derived macrophages [19],
neutrophils [20], and in vitro models [21]. In addition to
rs1143679, speculation has occurred about a secondary in-
dependent SLE association within ITGAM due to a second
nonsynonymous variant rs1143683 (A858V) [22]. Because
precedence exists for the presence of multiple effects
in risk loci of complex diseases, this requires further
evaluation [23].
Here we report the identification of two novel, case-
specific rare variants in ITGAM after resequencing of this
locus in cases of European ancestry. Both variants, F941V
and G1145S, were functionally damaging, as measured by
an in vitro model of CR3-mediated phagocytosis, but the
common A858V (rs1143683) variant was functionally neu-
tral. Furthermore, neither F941V nor G1145S was observed
in the follow-up genotyping of 2107 and 949 SLE cases, re-
spectively. This study shows the importance of multiple ap-
proaches to the analysis of rare variants, and the need for
better methods to estimate contributions, before we dismiss
the importance of this large body of genetic variation.
Methods
The 454 sequencing and analysis
Genomic DNA from 73 SLE patients meeting American
College of Rheumatology criteria underwent whole-genome
amplification (Qiagen Repli-G, Hilden, Germany). Ethical
approval was given by London Multicentre Research Ethics
Committee, and participants gave written consent. Stand-
ard (KOD polymerase, Merck) and long-range (Sequalprep,
Invitrogen, CA, USA) PCR reactions were carried out in 13
amplicons, giving products between 600 base pairs and 4
kb in length, covering 24 kb of the ITGAM gene, including
all 30 exons (see Additional file 1). The PCR products were
run on an agarose gel and purified by using the Qiagen
MinElute 96 UF PCR Purification Kit. Seven amplicons
greater than 1.5 kb were pooled and sheared to fragments
of 500 to 800 bp on the Covaris E210. The six short PCR
products were added to the sheared products, and each
pool was tagged with a unique DNA barcode by using the
Parallel Tagged Sequencing (PTS) protocol [24], starting at
the blunt-end repair step. The barcoded PCR products
were quantified by using the Invitrogen Quant-iT Picogreen
dsDNA kit and combined into a single pool by using 10 ng
of each tagged sample.
Dephosphorylation and restriction digestion was car-
ried out according to the PTS protocol, and the pool of
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454 Titanium library preparation according to the man-
ufacturer’s protocol (GS FLX Titanium General Library
Preparation Method Manual, v5.3.2), starting at step 3.5.
Library quality was checked by using an RNA Pico 6000
assay on the Agilent Bioanalyser and quantified by using
a RiboGreen assay (Thermo Fisher Scientific, MA, USA)
with the Nanodrop 3300 fluorospectrometer. The library
was diluted to 1 × 108 molecules/μl, amplified and se-
quenced according to the manufacturer’s protocol for 454
GS FLX sequencing. With 896,206 reads that passed filters,
an average coverage of 105× was achieved; 88% of the sam-
ples were covered at a level sufficient for variant calling
(more than 10 reads) in at least 80% of the target region.
Additional PCRs (KOD polymerase, Merck, Darmstadt,
Germany) were generated covering exons 8, 13 and 14 due
to low coverage in the 454 data. Capillary sequencing
of these amplicons used the 3730xl platform (Applied
Biosystems, CA, USA).
The 454 sequence read demultiplexing used ”untag” soft-
ware [24]; base calling used Pyrobayes [25]; and alignment
to the reference genome used BWA [26]. Variant calling
was carried out by using GATK [27] without duplicate
read removal, by using hard filters: coverage at least 10-
fold; genotype quality threshold, 50; SNP quality threshold,
30; and allele balance threshold, 0.75.
The presence of novel variants was confirmed inde-
pendently by PCR amplification of native genomic DNA
followed by capillary sequencing (see Additional file 2).
G1145S was genotyped in 949 additional SLE cases with
capillary sequencing by using the following primers: 5′
GGCTTCTTCAAGCGGCAATA and 5′ GTCCTGTCG
GGGATACTTCG. F941V was genotyped in 2,107 add-
itional SLE cases on an Illumina Custom 384 chip.
Site-directed mutagenesis
10 ng of a pcDNA3.1-CD11b vector (Life technologies,
Paisley, UK) was mutated to contain one of four
ITGAM variants by using the PCR-based QuikChange II
XL Site-Directed Mutagenesis kit (Agilent Technologies,
Stockport, UK), followed by transformation of XL-10 Gold
Ultra-competent cells, as per the manufacturer’s instruc-
tions. The primers used for the introduction of each of
the variants were as follows: M441T 5′-gcagaacactgg
cacgtgggagtccaacg-3′ and 5′-cgttggactcccacgtgccagtgttctgc-
3′; A858V 5′-ccgaagtgtctggggtcttgaagagcaccag-3′ and 5′-
ctggtgctcttcaagaccccagacacttcgg-3′; F941V 5′-tctccactaaa
tatctcaacgtcacggcctcagagaat-3′ and 5′-attctctgaggccgtgacg
ttgagatatttagtggaga-3′; G1145S 5′-atgagtgaagggagtcccccgg
ggg-3′ and 5′-cccccgggggactcccttcactcat-3′.
Transient transfections
COS-7 cells (ATCC, USA) were maintained in 10% FBS
DMEM (Life Technologies); 1 × 106 cells were co-transfected with one of five pcDNA3.1-CD11b vectors
(WT, M441T, A858V, F841V, or G1145S) together
with 1.25 g pcDNA3.1-CD18 by using nucleofection
(Nucleofector II; Lonza, Basel, Switzerland). In duplicate,
40 × 104 cells were added to an acid-cleaned coverslip in a
24-well plate. The remaining transfected cells were cul-
tured for expression screening with flow cytometry.
Flow cytometry
One or two days after transfection, cell-surface expression
of CR3 was measured by using a PE-conjugated anti-
CD11b (clone ICRF44) antibody and PE-conjugated iso-
type control. Transfected cells were stained in the dark
for 30 minutes on ice and processed on a BD FACS Canto
II flow cytometer. The percentage of CR3-positive cells
was estimated, and the mean fluorescence intensity (MFI)
measured, by using FlowJo software v.7.6.4. A paired t test
was used to compare the MFI of the CR3-positive cell
population. No significant difference in cell-surface ex-
pression of CD11b was observed between WT (n = 5,
mean ± SD; 14,445 ± 6,982) and M441T (15,017 ± 7,993),
A858V (12,377 ± 5,130), F941V (14,327 ± 4,358), or
G1145S (12,767 ± 5,028) CD11b transfected cells.
Phagocytic assay
This was carried out on the same day as the flow-cytometry
expression analysis. The method used is identical to that in
our previously published work [19] and has been used ex-
tensively as an in vitro model for phagocytic receptors
[28,29]. In summary, sheep red blood cells (sRBCs) were
coated with anti-sheep IgG at room temperature for 1
hour, followed by incubation at 37°C for 20 minutes with
C5-depleted serum to form iC3b-opsinized sRBC
(sRBCiC3b). Transfected COS-7 cells were challenged with
sRBCiC3b for 30 minutes at 37°C. External sRBCiC3b were
labeled with an Alexa-488 conjugated anti-IgG antibody
and, after fixation and permeabiliation, both internal and
external sRBCiC3b were labeled with an Alexa555-
conjugated anti-IgG antibody. COS-7 nuclei were stained
with DAPI. A Zeiss Axiophot fluorescent microscope was
used visually to analyze the coverslips.
Analysis
Associated RBCs are double-stained with Alexa-488 and
Alexa-555 and are therefore visible under both fluorescent
filters. A phagocytic event was characterized by the absence
of the Alexa-488 stain. We measured the association index
(AI, mean number of engaged sRBCiC3b/100 COS cells),
phagocytic index (PI, mean number of phagocytosed
sRBCiC3b/100 COS cells), and percentage phagocytosis (%
P, mean percentage phagocytosis/COS cell). A mean num-
ber of 67 COS-7 cells were counted from at least two cov-
erslips per assay. Comparisons were made between WT
Roberts et al. Arthritis Research & Therapy 2014, 16:R114 Page 4 of 11
http://arthritis-research.com/content/16/3/R114and variants by using paired two-tailed t tests on Prism5
software (GraphPad, CA, USA).
Results
Two novel non-synonymous variants discovered through
ITGAM resequencing
We used a candidate-gene approach and resequenced
ITGAM by using the high-throughput 454 GS FLX plat-
form in 73 SLE cases in search of putative rare variants.
Then 24 Kb of the ITGAM locus was sequenced, cover-
ing all 30 exons and every intron/exon boundary. Two
rare novel variants were identified in one patient sample
each, F941V and G1145S (Table 1), and were confirmed
by capillary sequencing after PCR amplification of na-
tive genomic DNA (Additional file 2). F941V was fur-
ther genotyped on an Illumina Custom 384 Chip in
2,107 SLE cases of European ancestry. G1145S did not
pass QC analysis of this genotyping method, possibly
because of its close proximity (3 bp) to the common
polymorphism P1146S, and so was genotyped with ca-
pillary sequencing in 949 SLE cases of European ances-
try. Neither variant was observed again in these
additional cases; therefore, we can estimate the minor
allele frequencies of these variants to be F941V,
≤0.0002, and G1145S, ≤0.0005.
CD11b codons 941 and 1145 are located in the
membrane-proximal extracellular domain and the short
cytoplasmic tail of the protein, respectively (Figure 1).
Table 1 shows the in silico estimates of pathogenicity by
using PolyPhen and SIFT. F941V was predicted to be
deleterious, and G1145S was predicted to be benign, by
both algorithms.
We used two large-scale publicly available sequencing
project datasets to screen ITGAM on the chromosomes of
healthy controls of European ancestry. Neither variant,
F941V or G1145S, is described in the 1,000 chromosomes
of European ancestry in the 1,000 Genomes project [32],
nor are they described in the 8,600 European-American
chromosomes of The National Heart Lung and Blood In-
stitute (NHLBI) Exome Variant Server [33]. Therefore,
both variants are novel, and, if not private, they are present
at a frequency below 0.0001 in healthy individuals of
European ancestry. It is worth noting that neither
variant is found in the other populations included in theTable 1 Summary of common polymorphisms and rare varian
Variant Chromosomes from resequencing study with minor alle
M441T 21
A858V 33
F941V 1
G1145S 1
PolyPhen-2 [30] categorizes mutations as benign, possibly damaging, or probably d
predicts variants to be deleterious, given an output value <0.05.databases. This was expected, given that rare variants
will be population specific.
MultAlin [34,35] was used to compare the protein se-
quences of the four CD11 molecules that pair with CD18
as part of the β2 integrin family (Figure 2). The four pro-
teins, CD11a, CD11b, CD11c, and CD11d, are encoded by
ITGAX, ITGAM, ITGAL, and ITGAD, respectively. The
phenylalanine (F) residue at CD11b codon 941, which is
located in the membrane-proximal extracellular domain,
is conserved across all four polypeptide sequences. The
Glycine (G) residue at CD11b codon 1,145 is not shared
with any of the other three CD11 proteins. No homology
occurs at this relative position among any of the CD11
amino acid sequences. The short cytoplasmic tails of the
CD11 molecules vary in length and sequence, and the dif-
ferences observed are likely to be crucial for their varying
functions, and/or intracellular signaling properties. Data
from the UCSC Genome Browser [36] indicated that both
CD11b residues, F941 and G1145, are highly conserved
across mammalian species (data not shown).
In vitro analyses of rare and common variants
We used transiently transfected COS-7 cells to measure
the effect of newly identified ITGAM rare variants on the
binding and phagocytosis of iC3b-coated sheep red blood
cells (sRBCiC3b), in addition to CR3 cell-surface expres-
sion. Additionally, we included the two common poly-
morphisms M441T (rs11861251) and A858V (rs1143683),
which are in low (r2 = 0.017) and relatively high (r2 =
0.551) LD, respectively, with R77H in European popula-
tions, in our in vitro analyses. LD scores were calculated
with 1000 Genomes Pilot 1 CEU data set by using SNAP
Pairwise LD [37].
To test whether the nonsynonymous variants affected
iC3b binding, we measured the ability of transiently trans-
fected COS-7 cells to associate with iC3b-opsinized sheep
red blood cells (sRBCiC3b) by using an Association Index.
No significant difference was observed when variant
CD11b was compared with WT, indicating that none of
the four variants (M441T P = 0.79; A858V P = 0.69; F941V
P = 0.61; G1145S P = 0.85) affects the iC3b-binding ability
of CR3 (Figure 3). Given that the four variants are located
outside the iC3b-binding site of the protein (Figure 1), this
was an expected result.ts used for in vitro study
le (total = 146) PolyPhen-2 SIFT
Benign (0) Tolerated (0.63)
Benign (0.001) Tolerated (0.35)
Probably damaging (1.00) Damaging (0)
Benign (0.319) Tolerated (0.5)
amaging, based on pairs of false-positive rate (FPR) thresholds. SIFT [31]
Figure 1 ITGAM transcript, CD11b primary protein domains, and CR3 protein. (A) ITGAM genomic organization showing relative positions
of common polymorphisms (R77H, M441T, A858V) and novel rare variants (F941V, G1145S). (B) Primary protein domains of CD11b and the
relative location of the missense variants. The β-propellor domain is shown in dark blue; the ligand-binding I-domain is shown in green; light blue
represents the other extracellular domains; the transmembrane domain is shown in yellow, and the short cytoplasmic tail is represented in
orange. (C) A cartoon diagram of the CR3 protein (Protein domain ratios = extracellular/transmembrane/cytoplasmic = 1:6:6). The same colors as
(B) are used to represent the various domains; CD18 is shown in light purple. Asterisks are used to indicate the position of missense variants used
in the functional studies: M441T, A858V, F941V, and G1145S.
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0.002; Figure 4) and the percentage phagocytosis (P =
0.006; Figure 5), and the G1145S variant significantly im-
paired percentage phagocytosis (P = 0.0232; Figure 5),
when compared with the WT (see Additional file 3).
Neither of the two common polymorphisms had an effect
on the phagocytosis of sRBCiC3b as measured by the Phago-
cytic Index (M441T, P = 0.74; A858V, P = 0.92; Figure 4)
and percentage phagocytosis (M441T, P = 0.70; A858V,
P = 0.47; Figure 5).
The same transient transfection COS-7 model had
previously been used by our group to demonstrate the
deleterious effects of the SLE-associated missense poly-
morphism, R77H, on iC3b-dependent phagocytosis [19].
We used the mean reduction in percentage phagocytosis
to compare the results of this study with that of theprevious R77H study (Figure 6). As seen here, G1145S
(26%) has a comparable magnitude of effect to that of
R77H (31%), whereas F941V (61%) has an even greater
effect on phagocytosis.
Discussion
Through resequencing ITGAM in SLE patients of
European ancestry, we identified two novel, case-specific
variants. The in vitro model shows that both these
variants, G1145S and, more strongly, F941V, impair
CR3-mediated phagocytosis of iC3b-coated targets. The
observed detrimental impact on protein function is of a
similar (G1145S), or greater (F941V), magnitude to that of
the common SLE-associated polymorphism R77H (which
was associated with a 31% reduction in phagocytosis in an
earlier article) [19]. Two factors support the importance of
Figure 2 Comparisons of CD11 amino acid sequences. CD18 pairs with CD11b, CD11a, CD11c, and CD11d, and together, these make up the
β2 integrin family. The four CD11 protein sequences (encoded by ITGAM, ITGAX, ITGAD, and ITGAL) were aligned by using MutAlin. The numbers
indicate the CD11b codons, and all other sequences are aligned relative to this. F941 and G1145 of CD11b are indicated by arrows. The
phenylalanine at codon 941 is present across all four CD11 polypeptides; the glycine at codon 1145 is not found in any other CD11 polypeptide.
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tence of common and rare variants in genetic loci predis-
posing to the same disease biology, and second, they
emphasize the role of underfunctioning ITGAM variants
in SLE pathogenesis.Figure 3 Association of CR3-expressing COS-7 cells with sRBCiC3b. Ass
sRBCiC3b/100 COS-7 cells. No significant difference was observed between W
F941V (P = 0.61).The targeted resequencing of loci harboring disease-
associated common polymorphisms has successfully identi-
fied novel rare variants in a number of other complex
genetic diseases such as inflammatory bowel disease, psoria-
sis, and asthma [13,14,38]. Recent studies in schizophreniaociation Index = mean number of associated (internal and external)
T and M441T (P = 0.79), A858V (P = 0.65), G1145S (P = 0.85), or
Figure 4 Phagocytosis of sRBCiC3b by CR3-expressing COS-7cells as measured with the Phagocytic Index. Phagocytic Index, mean
number of internal sRBCiC3b/100 COS-7 cells. F941V significantly impairs phagocytosis (P = 0.002). No significant difference observed between WT
and either common polymorphism M441T (P = 0.74) and A858V (P = 0.92), or the rare variant G1145S (P = 0.37).
Figure 5 Phagocytosis of sRBCiC3b by CR3-expressing COS-7cells as measured with percentage phagocytosis. Percentage phagocytosis,
mean percentage phagocytosis/COS-7 cell. Both rare variants F941V and G1145S significantly impair phagocytosis (P = 0.006 and 0.0232,
respectively). No significant difference was observed between WT and either common polymorphism M441T (P = 0.70) and A858V (P = 0.47).
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Figure 6 Percentage reduction in phagocytosis of CD11b
variants compared with WT. Comparison of the functional impact
of the two rare variants with that of the SLE-associated R77H
(previously published data [19]). Mean and SEM are shown.
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whole-exome sequencing but failed to identify a single vari-
ant that reached study-wide significance, despite large-scale
genotyping in follow-up cohorts. The schizophrenia study
reported that 23% of case-specific variants from the initial
sequencing cohort were not observed again in the follow-
up cohort [39]. As demonstrated by these two studies, indi-
vidual rare variants may never reach statistical significance
for disease association. In our follow-up genotyping, 2,107
and 949 additional SLE cases were found to be wild-type
for F941V and G1145S, respectively.
To assess the contribution of these novel ITGAM vari-
ants to disease biology, we additionally estimated their
functional impact. We were able to do this by using a ro-
bust functional assay [28] that had previously proven suc-
cessful in delineating function of the common ITGAM
R77H variant [19]. Our work does not contribute to the
estimate of overall genetic variance explained for SLE, but
it does add evidence to the functional importance of the
ITGAM locus to SLE susceptibility.
Furthermore, this study is another example of rare var-
iants located in genetically associated loci whose contri-
bution to disease risk cannot be estimated by statistical
models alone because of their extremely low frequencies.
However, given the demonstrated functional impact of
these variants, their contribution cannot be dismissed.
A case report of a CR3 defect in an SLE patient was pre-
viously assumed to be a result of a rare genetic variant
[40]. Until additional methods of analysis are available,
the contribution of rare variants to complex diseases
should not be dismissed on the basis of non-significant
statistical associations alone.Although we observed clear functional similarities be-
tween the novel rare variants and R77H, the magnitude
of this functional effect was different between variants,
being stronger for variant F941V than for G1145S or
common variant R77H. This raises an important point
about the rare variant paradigm, which is often repre-
sented as a direct negative correlation between allele
frequencies and disease risk [41]. Our in vitro model in-
dicates that within a single gene, functional variants may
vary considerably both in frequency (MAF = 0.2 versus
MAF ≤0.0005) and functional magnitude.
Defective phagocytosis is a robust paradigm in SLE biol-
ogy [42], but of course may not be the only mechanism by
which impaired CR3 function predisposes to SLE risk. It is
possible, then, that F941V and/or G1145S have variable ef-
fect sizes on other CR3 functions, such as the inhibition of
Toll 7/8-induced proinflammatory cytokines; however, in
the absence of ex vivo cells from multiple healthy individ-
uals carrying these mutations, or additional suitable in vitro
assays, we lack a sufficient model for this [19,43]. We
recognize that it is difficult to estimate directly the contri-
bution of these rare variants to SLE risk; however, we be-
lieve that because their impact on phagocytosis is equal to,
or greater than, that of R77H, their effect should not be dis-
missed. This risk is likely to be modest (as it is for R77H),
supported by the identification of F941V, which has the
greatest impact on CR3 function, in unaffected family
members through capillary sequencing.
Finally, both patients with ITGAM rare variants de-
scribed here were included as part of a recent SLE GWAS
(J. Bentham, D. L. Morris, et al., 2014, unpublished data)
and their risk scores (allele count*ln(OR)) fall within 1 SD
of the mean risk score for all cases (personal communica-
tion). If a relatively small number of rare variants were to
contribute to large amount of the genetic variance of SLE,
we might expect the two patients’ risk scores, obtained
from their genomic composition of associated common
variants, to be relatively low. Together with the compar-
able functional impact of G1145S and R77H, our work
suggests that some individual rare variants may contribute
less to the genetic variance of complex diseases than
is currently hypothesized, but it is possible that, on a
population-wide scale, the presence of individual rare vari-
ants with weak effect size is a common phenomenon and,
in total, accounts for much missing heritability, despite
the current lack of appropriate statistical tools. As we have
demonstrated, if they were located in known susceptibility
loci and if the right functional assay were available, they
might be relatively easy to find. The majority, however, are
likely to remain undiscovered.
As well as demonstrating a general aspect of rare-variant
discovery, our data also expand on our specific understand-
ing of the role of ITGAM variants in SLE pathogenesis.
First, we have resolved some uncertainty in the genetic
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fect of ITGAM SNP rs1143683 (A858V). SNP rs1143683
(A858V) and rs1143679 (R77H) are in relatively high LD
(r2 = 0.55) in European populations, and rs1143683 has
been suggested as a secondary independent association sig-
nal within ITGAM in a Thai population [22]. We wished to
clarify this issue by including the A858V polymorphism in
our in vitro model, along with another polymorphism,
rs11861251 (M441T), which is not a part of the same
disease-associated haplotype (r2 = 0.017), which we en-
visaged as a negative control. We found that neither
the A858V nor the M441T mutations affect the CR3-
mediated phagocytosis of iC3b-coated targets.
A recent publication demonstrated a functional impact
of ITGAM polymorphisms on ex vivo neutrophil func-
tions, independent of R77H [44]. There is perfect LD be-
tween rs1143683 (A858V) and rs1143678 (P1146S), and
for this reason, the functional impact of these variants
could be analyzed only on a haplotype basis. Even
though they report a significant reduction in phagocyt-
osis in individuals with A858V/P1146S variant neutro-
phils, they hypothesize that the affect is attributable to
the less-conservative P1146S amino acid change. Our re-
sults support this hypothesis of the functional neutrality of
A858V. Of particular interest, the patient who harbors the
G1145S rare variant is also heterozygous for the P1146S
polymorphism. Through using the IGV program to view
aligned 454 sequencing reads, we can see that the G1145S
rare variant and P1146S polymorphism are in phase on
the chromosome. G1145S had the least severe impact on
phagocytic function (26% reduction); however, a functional
alteration to two sequential amino acids could indeed have
an impact greater than the additive effect of the G1145S
and P1146S variants considered independently. This pa-
tient is also heterozygous for the associated R77H poly-
morphism (of note, the patient with F941V is homozygous
WT), so it is possible that the CR3 functions of this person
are severely affected in vivo. The phenomenon of an addi-
tive functional effect of both rare and common variants
within the same polypeptide molecule is of particular
interest when considering the contribution of rare variants
to complex disease susceptibility.
Our functional results also emphasize that impaired
phagocytosis of iC3b opsonized particles, a consequence
of defective ”outside-in” signaling is one, but clearly not
necessarily the only, functional mechanism underlying
the association between specific ITGAM risk variants
and SLE. It is notable that all three functional variants,
R77H, F941V, and G1145S, are located in different
domains of the CD11b polypeptide (Figure 1) but have
similar effects on signaling. None appears directly to
influence known ligand-binding sites [45], but clearly spe-
cific amino acids throughout CD11b, from the N-terminal
β-propeller (R77) domain through to the C-terminalcytoplasmic tail (G1145), are important in mediating
CR3 outside-in signals to the cytoplasm. As seen
with R77H, variants can affect function even if not in
classically identified-ligand binding or intracellular
signaling domains. This effect may be due to necessary
interactions between CD11b and CD18 or due to the re-
quirement for large conformational changes occurring
during integrin activation/signaling [46].
The ”hypothesis-free” GWAS method has proven suc-
cessful in highlighting novel disease-associated poly-
morphisms for further functional analysis, but lacks
statistical power to prove the association of most rare vari-
ants with disease. Recent approaches have identified rare
variants in disease-associated loci very successfully, but esti-
mating their contribution to disease risk has proven diffi-
cult. Conclusions are leading toward the notion that rare
variants contribute little toward genetic variance [15]. We
demonstrated that once the functional consequence of a
common variant has been clearly elucidated, this knowledge
can be reapplied to provide proof of a role for additional
candidate rare variants at the same locus. In a relatively
small resequencing project, we used this approach to iden-
tify two functional rare variants at the ITGAM locus. This
study suggests that further screening of ITGAM for rare
variants in a larger cohort of SLE cases promises to be
worthwhile. If an association-based approach alone were
applied in this study, there would be no evidence of any po-
tential contribution of these rare variants to SLE pathogen-
esis. However, it is not possible to disregard these variants,
given their genetic location, conservation, and deleterious
effects on receptor function. If each of the 52 known SLE-
susceptibility loci contains a similar high number of modest
effect-size rare variants, then their contribution to the over-
all genetic component of disease susceptibility will be not
inconsiderable. However, perhaps we currently lack the cor-
rect tools for estimating the contribution of rare variation
to complex disease susceptibility.Conclusion
We have identified two novel rare variants in the SLE
susceptibility gene, ITGAM, and demonstrated their
functional effects. However, because of their extremely
low frequencies, they are not statistically associated with
disease risk. This study questions the current notion of
dismissing the contribution of very rare variants on
purely statistical analyses alone. Our results add further
evidence to the functional importance of ITGAM in SLE
pathogenesis through impaired phagocytosis.Additional files
Additional file 1: Table S1. Primer sequences used to generate
amplicons covering coding regions of ITGAM for 454 library preparation.
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sequencing. Electropherogram images showing the Sanger Sequencing
validation of the two rare variants.
Additional file 3: Table S2. Percentage phagocytosis of WT and variant
CD11b-transfected COS-7 cells. Raw data comparing the percentage
phagocytosis of WT and variant CD11b-transfected cells across five
independent assays.
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